Hwail Pharmaceutical Co.Ltd (061250) — Cash Flow Reinvestment Rate
Hwail Pharmaceutical Co.Ltd (061250) has a Cash Flow Reinvestment Rate of 0.21x as of September 2025, reinvesting ₩1.42 Billion (capex ₩1.39 Billion plus investments ₩35.01 Million) from operating cash flow of ₩6.82 Billion. Explore how much does Hwail Pharmaceutical Co.Ltd reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hwail Pharmaceutical Co.Ltd Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for Hwail Pharmaceutical Co.Ltd across 10 annual periods. Also explore 061250 total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year capital reinvestment analysis for Hwail Pharmaceutical Co.Ltd. For live market cap and broader valuation context, see market cap of Hwail Pharmaceutical Co.Ltd.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 7.24x | ₩84.20 Billion | ₩11.63 Billion | ₩34.63 Billion | ▲ +132.8% |
| 2023 | 3.11x | ₩21.84 Billion | ₩7.02 Billion | ₩2.10 Billion | ▲ +59.1% |
| 2021 | 1.95x | ₩39.26 Billion | ₩20.09 Billion | ₩2.47 Billion | ▲ +564.1% |
| 2019 | 0.29x | ₩1.09 Billion | ₩3.69 Billion | ₩1.09 Billion | ▲ +36.1% |
| 2018 | 0.22x | ₩1.55 Billion | ₩7.17 Billion | ₩1.55 Billion | ▲ +250.9% |
| 2017 | 0.06x | ₩513.62 Million | ₩8.34 Billion | ₩513.62 Million | ▼ -91.9% |
| 2016 | 0.76x | ₩7.29 Billion | ₩9.58 Billion | ₩413.00 Million | ▼ -52.4% |
| 2013 | 1.60x | ₩11.16 Billion | ₩6.97 Billion | ₩9.18 Billion | ▼ -79.2% |
| 2012 | 7.69x | ₩7.72 Billion | ₩1.00 Billion | ₩7.72 Billion | ▲ +1034.5% |
| 2011 | 0.68x | ₩5.32 Billion | ₩7.86 Billion | ₩5.32 Billion | — |